

# Associations with Corneal Hysteresis in a Population Cohort

## Results from 96 010 UK Biobank Participants

Bing Zhang, MBBS, MD,<sup>1</sup> Yusrah Shweikh, MBBS, FRCOphth,<sup>2,3</sup> Anthony P. Khawaja, PhD, FRCOphth,<sup>2,3</sup> John Gallacher, PhD, FFPH,<sup>1</sup> Sarah Bauermeister, MSc, PhD,<sup>1</sup> Paul J. Foster, PhD, FRCS(Ed),<sup>2,3</sup> on behalf of the UK Biobank Eye and Vision Consortium\*

**Purpose:** To describe the distribution of corneal hysteresis (CH) in a large cohort and explore its associated factors and possible clinical applications.

**Design:** Cross-sectional study within the UK Biobank, a large cohort study in the United Kingdom.

**Participants:** We analyzed CH data from 93 345 eligible participants in the UK Biobank cohort, aged 40 to 69 years.

**Methods:** All analyses were performed using left eye data. Linear regression models were used to evaluate associations between CH and demographic, lifestyle, ocular, and systemic variables. Piecewise logistic regression models were used to explore the relationship between self-reported glaucoma and CH.

**Main Outcome Measures:** Corneal hysteresis (mmHg).

**Results:** The mean CH was 10.6 mmHg (10.4 mmHg in male and 10.8 mmHg in female participants). After adjusting for covariables, CH was significantly negatively associated with male sex, age, black ethnicity, self-reported glaucoma, diastolic blood pressure, and height. Corneal hysteresis was significantly positively associated with smoking, hyperopia, diabetes, systemic lupus erythematosus (SLE), greater deprivation (Townsend index), and Goldmann-correlated intraocular pressure (IOPg). Self-reported glaucoma and CH were significantly associated when CH was less than 10.1 mmHg (odds ratio, 0.86; 95% confidence interval, 0.79–0.94 per mmHg CH increase) after adjusting for covariables. When CH exceeded 10.1 mmHg, there was no significant association between CH and self-reported glaucoma.

**Conclusions:** In our analyses, CH was significantly associated with factors including age, sex, and ethnicity, which should be taken into account when interpreting CH values. In our cohort, lower CH was significantly associated with a higher prevalence of self-reported glaucoma when CH was less than 10.1 mmHg. Corneal hysteresis may serve as a biomarker aiding glaucoma case detection. *Ophthalmology* 2019;126:1500-1510 Crown Copyright © 2019 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology



Supplemental material available at [www.aaojournal.org](http://www.aaojournal.org).

It is well recognized that variation in central corneal thickness (CCT) influences the accuracy of intraocular pressure (IOP) measurements.<sup>1-3</sup> It has also been hypothesized that CCT independently influences the risk of glaucoma, with thin CCT evidenced in those at highest risk.<sup>4</sup> However, this view is not universally accepted, because one particular high-risk group (African Americans) typically has thinner CCT than people of European heritage.<sup>5</sup> A plausible alternative explanation is that thin CCT is a biomarker for race and identifies those at highest risk, attributable to other ocular or systemic factors.

Corneal hysteresis (CH) offers an alternative index of corneal biomechanical characteristics to CCT and reflects the viscoelastic damping effect of corneal tissues, defined as the difference in air pulse pressure between inward and outward applanation forces.<sup>6,7</sup> Recent evidence indicates

CH can provide valuable information related to the presence, progression, and response to therapy of glaucoma.<sup>8,9</sup> Corneal hysteresis can be measured simultaneously with IOP using noncontact tonometry with augmented functionality. Differences in CH have been reported not only in glaucoma but also in many systemic diseases, including thyroid eye disease,<sup>10</sup> rheumatoid arthritis,<sup>11</sup> psoriasis,<sup>12</sup> acromegaly,<sup>13</sup> and myotonic dystrophy,<sup>14</sup> which suggests CH may play a clinical role in fields other than ophthalmology. Previous studies on CH are limited by small sample sizes.<sup>15,16</sup> The distribution of CH and its associations with demographic, ocular, and systemic variables remain to be accurately determined and confirmed in a large sample.

The UK Biobank is one of the largest prospective population cohort studies in the world. In this study, we aimed

to report the distribution of CH by age, sex, and ethnicity, and explore its associations, including the relationship between CH and self-reported glaucoma. We also tested the association between CH and 16 self-reported diseases selected on the basis of existing literature.<sup>10-13</sup>

## Methods

### Study Population

The UK Biobank is a multisite community-based cohort study with 502 544 participants. All UK residents aged 40 to 69 years who registered with the National Health Service and lived within 25 miles of any of the 22 assessment centers were invited to join the study. The initial visit assessments took place between 2006 and 2010. Eye assessments were carried out from 2009 in 6 recruitment centers (5 in England and 1 in Wales) that enrolled 133 953 participants. The UK Biobank study was approved by the North West Multi-centre Research Ethics Committee (Reference No. 06/MRE08/65) and adhered to the tenets of the Declaration of Helsinki. Written consent was obtained from every participant. More detailed information and protocols for UK Biobank are available online (<http://www.ukbiobank.ac.uk/>).

Ethnicity was self-reported by participants and selected from white, Asian, black, Chinese, mixed, and other ethnic backgrounds. Socioeconomic status was derived using the Townsend deprivation index estimated using residence postcodes. This represents an indicative measure of economic deprivation in an area, and higher scores indicate worse socioeconomic status.<sup>17</sup>

### Measurements

Cohort characteristics and ophthalmic measures have been described.<sup>18</sup> Visual acuity was measured using a bespoke computerized logarithm of the minimum angle of resolution acuity measure conforming to British Standard BS4274-1968,<sup>19</sup> with left eye following right eye. Autorefractometry was performed with the RC5000 Auto Refkeratometer (Tomey, Tokyo, Japan). After measuring visual acuity and refraction, CH and Goldmann-correlated IOP (IOPg) were measured with the Reichert Ocular Response Analyzer (ORA, Reichert, Inc., Depew, NY) according to a predetermined protocol (available at <http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=100236>). Participants who had any eye surgery within the preceding 4 weeks were excluded from tests. The measurements were performed first in the right eye and taken only once in each eye. If participants blinked during the test, a further measurement was attempted.

Blood pressure was measured with an automatic blood pressure monitor, HEM-70151T (Omron, Hoofddorp, The Netherlands). Two measurements were performed for each participant, and the average was used for analysis if the values of both were available. Height was measured with the Seca 202 instrument (Seca, Birmingham, UK).

### Medical History

All diseases were self-reported by participants via verbal interviews conducted by trained nurses or via touchscreen questionnaires. Self-reported eye disorder status was collected in the verbal interview or selected by participants from a list of eye disorders in response to the question “Has a doctor told you that you have any of the following problems with your eyes?” The list of eye disorders was as follows:


1. Diabetes-related eye disease.
2. Glaucoma.

3. Injury or trauma resulting in loss of vision.
4. Cataract.
5. Macular degeneration.
6. Other serious eye condition.
7. None of the above.
8. Prefer not to answer.
9. Do not know.

Smoking and alcohol consumption were self-reported via touchscreen questionnaires. Smoking status was trichotomized for the purpose of analysis to current smokers, ex-smokers, and those who have never smoked. Alcohol consumption was pentachotomized to daily/almost daily, weekly or more often, monthly or more often, occasional, and never. The use of IOP-lowering medications was recorded by trained interviewers. Only currently and regularly used ones were recorded. Intraocular pressure-lowering medication status was dichotomized to user and nonuser for analysis. More detailed information about all variables is available online (<http://biobank.ctsu.ox.ac.uk/crystal/index.cgi>).

### Eligibility Criteria

All participants who had available ORA data (CH and IOPg) in the left eye were used for this analysis. Participants who met any exclusion criteria in Figure 1 were excluded from the analyses; 0.5% of participants who were younger than 40 years or older than 69 years of age were excluded on the basis of the UK Biobank eligibility criteria. Extreme values (lowest 0.5% and highest 0.5%) of CH and IOPg may represent measurement errors and were excluded. We excluded participants with a



**Figure 1.** Flowchart showing participants included for analysis. CH = corneal hysteresis; D = diopter; IOPg = Goldmann-correlated intraocular pressure.

Table 1. Distribution of Corneal Hysteresis (mmHg) Stratified by Age, Gender, and Ethnicity in 92 137 Left Eyes without Self-Reported Glaucoma\*

	40–44 Yrs	45–49 Yrs	50–54 Yrs	55–59 Yrs	60–64 Yrs	65–69 Yrs	P <sup>†</sup>	Total
<b>Female</b>								
White	11.3±1.9 (4127)	11.2±1.8 (5600)	11.0±1.8 (6877)	10.9±1.9 (8099)	10.7±1.8 (11 768)	10.5±1.8 (8449)	1.82×10 <sup>-174</sup>	10.8±1.8 (44 920)
Asian	10.7±1.8 (315)	10.7±1.7 (292)	10.7±1.8 (323)	10.2±1.7 (295)	10.6±1.7 (287)	10.2±1.8 (167)	2.62×10 <sup>-4</sup>	10.5±1.8 (1679)
Black	9.8±1.8 (364)	9.8±1.8 (482)	9.8±1.8 (434)	9.7±1.8 (243)	9.6±2.0 (204)	9.8±2.1 (152)	0.88	9.8±1.9 (1879)
Chinese	10.9±2.1 (39)	11.1±2.1 (47)	10.9±1.5 (43)	10.6±1.9 (58)	10.8±2.1 (39)	10.6±1.7 (24)	0.80	10.8±1.9 (250)
Mixed	10.8±1.8 (104)	10.4±1.8 (125)	10.6±1.6 (108)	10.8±1.8 (78)	10.7±1.8 (56)	10.2±1.7 (48)	0.24	10.6±1.8 (519)
Others	10.4±1.8 (147)	10.6±1.7 (177)	10.6±2.0 (173)	10.4±1.7 (147)	10.1±1.8 (140)	10.0±1.6 (75)	0.05	10.4±1.8 (859)
P <sup>‡</sup>	1.36×10 <sup>-52</sup>	3.91×10 <sup>-58</sup>	5.58×10 <sup>-40</sup>	2.47×10 <sup>-26</sup>	7.71×10 <sup>-17</sup>	1.52×10 <sup>-6</sup>	—	1.28×10 <sup>-150</sup>
Total <sup>§</sup>	11.1±1.9 (5125)	11.0±1.9 (6756)	10.9±1.9 (7999)	10.8±1.9 (8953)	10.7±1.8 (12 545)	10.5±1.8 (8952)	1.03×10 <sup>-122</sup>	10.8±1.9 (50 330)
<b>Male</b>								
White	10.8±1.9 (3484)	10.7±1.9 (4393)	10.6±1.9 (5125)	10.5±1.8 (6243)	10.3±1.9 (9897)	10.1±1.9 (8328)	9.35×10 <sup>-123</sup>	10.4±1.9 (37 470)
Asian	10.4±1.9 (388)	10.3±1.8 (321)	10.4±1.8 (276)	10.3±1.8 (294)	10.0±1.9 (254)	9.9±1.8 (244)	0.001	10.2±1.8 (1777)
Black	9.7±2.0 (292)	9.4±1.8 (319)	9.4±1.7 (232)	9.4±2.0 (193)	9.2±1.7 (129)	9.2±2.0 (122)	0.08	9.4±1.9 (1287)
Chinese	11.4±1.3 (17)	10.9±2.4 (25)	10.6±2.0 (24)	10.7±2.4 (27)	11.0±2.0 (27)	10.2±1.7 (20)	0.53	10.8±2.1 (140)
Mixed	10.6±2.1 (66)	10.6±2.0 (86)	10.1±1.8 (49)	10.1±1.9 (36)	10.4±1.7 (37)	9.7±1.5 (33)	0.11	10.3±1.9 (307)
Others	10.2±1.7 (128)	10.2±1.8 (110)	10.1±2.0 (87)	10.5±1.7 (92)	10.1±1.7 (71)	10.1±2.0 (62)	0.78	10.2±1.8 (550)
P <sup>‡</sup>	3.94×10 <sup>-25</sup>	3.51×10 <sup>-35</sup>	5.55×10 <sup>-19</sup>	1.71×10 <sup>-11</sup>	2.77×10 <sup>-10</sup>	1.74×10 <sup>-7</sup>	—	2.90×10 <sup>-79</sup>
Total <sup>§</sup>	10.7±1.9 (4404)	10.6±1.9 (5296)	10.5±1.9 (5829)	10.4±1.8 (6919)	10.3±1.9 (10 491)	10.1±1.9 (8868)	3.40×10 <sup>-96</sup>	10.4±1.9 (41 807)
P <sup>  </sup>	1.87×10 <sup>-23</sup>	9.29×10 <sup>-29</sup>	1.30×10 <sup>-34</sup>	2.54×10 <sup>-39</sup>	1.04×10 <sup>-61</sup>	3.01×10 <sup>-36</sup>	—	9.42×10 <sup>-228</sup>
All <sup>§</sup>	10.9±1.9 (9529)	10.8±1.9 (12 052)	10.8±1.9 (13 828)	10.6±1.9 (15 872)	10.5±1.9 (23 036)	10.3±1.8 (17 820)	6.70×10 <sup>-234</sup>	10.6±1.9 (92 137)

\*Participants with self-reported glaucoma in either eye were excluded. Data in format, mean ± SD mmHg (n of included eyes).

<sup>†</sup>P value of 1-way analysis of variance of the means between different age groups.

<sup>‡</sup>P value of 1-way analysis of variance of the means between participants with different ethnicities.

<sup>§</sup>Ethnicity was unclear for 500 participants (224 female and 276 male), with mean CH of 10.3±1.9 mmHg (10.4±1.9 mmHg in female participants and 10.2±1.9 mmHg in male participants).

<sup>||</sup>P value of 1-way analysis of variance of the means between women and men from the same age groups.

Table 2. Linear Regression with Corneal Hysteresis as the Dependent Variable in 93 345 Left Eyes

Corneal Hysteresis	Univariable		Multivariable (n = 91 765)	
	Coefficient ( $\beta$ ) (95% CI)	P	Coefficient ( $\beta$ ) (95% CI)	P
Age/10 yrs	-0.26 (-0.27 to -0.24)	$7.19 \times 10^{-252}$	-0.33 (-0.35 to -0.32)	$<10^{-300}$
Gender (Ref. = female )	-0.40 (-0.43 to -0.38)	$1.42 \times 10^{-233}$	-0.19 (-0.23 to -0.16)	$2.07 \times 10^{-27}$
Ethnicity (Ref. = white)		$5.77 \times 10^{-221}$		
Asian	-0.28 (-0.34 to -0.22)	$5.37 \times 10^{-19}$	-0.46 (-0.53 to -0.40)	$2.08 \times 10^{-45}$
Black	-1.03 (-1.10 to -0.96)	$7.51 \times 10^{-205}$	-1.22 (-1.29 to -1.15)	$1.03 \times 10^{-260}$
Chinese	0.14 (-0.05 to 0.34)	0.14	-0.02 (-0.22 to 0.17)	0.80
Mixed	-0.15 (-0.27 to -0.03)	0.02	-0.39 (-0.51 to -0.26)	$8.63 \times 10^{-10}$
Others	-0.33 (-0.43 to -0.24)	$4.27 \times 10^{-12}$	-0.60 (-0.70 to -0.50)	$3.52 \times 10^{-34}$
DBP/10 mmHg	-0.12 (-0.13 to -0.11)	$5.67 \times 10^{-81}$	-0.08 (-0.09 to -0.06)	$1.29 \times 10^{-33}$
SBP/10 mmHg	-0.08 (-0.09 to -0.07)	$9.71 \times 10^{-124}$	—	—
Height/10 cm	-0.19 (-0.20 to -0.17)	$3.18 \times 10^{-173}$	-0.16 (-0.18 to -0.14)	$4.71 \times 10^{-61}$
Eyesight/logMAR	0.00 (-0.06 to 0.06)	0.98	—	—
Refractive error/D	0.02 (0.01–0.02)	$2.55 \times 10^{-8}$	0.03 (0.03–0.04)	$3.06 \times 10^{-26}$
IOPg/mmHg	0.02 (0.02–0.03)	$2.82 \times 10^{-38}$	0.03 (0.03–0.04)	$2.32 \times 10^{-67}$
Smoking (Ref. = Never smoker)		$4.04 \times 10^{-99}$		
Current smoker	0.46 (0.42–0.50)	$3.34 \times 10^{-100}$	0.42 (0.38–0.46)	$1.22 \times 10^{-84}$
Former smoker	0.05 (0.03–0.08)	$1.05 \times 10^{-4}$	0.10 (0.07–0.12)	$7.71 \times 10^{-13}$
Alcohol intake frequency (Ref. = never drinker)		0.26		
Occasional drinker	0.04 (-0.01 to 0.09)	0.15	—	—
Monthly or more, less often than every week	0.06 (0.01–0.12)	0.03	—	—
Weekly or more, less often than daily	0.05 (0.00–0.09)	0.048	—	—
Daily or almost daily	0.04 (-0.01 to 0.08)	0.15	—	—
Self-reported glaucoma	-0.70 (-0.82 to -0.57)	$1.29 \times 10^{-26}$	-0.52 (-0.64 to -0.39)	$1.13 \times 10^{-15}$
Diabetes	0.13 (0.07–0.19)	$3.50 \times 10^{-5}$	0.28 (0.22–0.34)	$1.25 \times 10^{-20}$
Townsend Index	0.01 (0.01–0.01)	$6.34 \times 10^{-7}$	0.01 (0.01–0.02)	$7.82 \times 10^{-8}$

CI = confidence interval; D = diopter; DBP = diastolic blood pressure; IOPg = Goldmann–correlated intraocular pressure; logMAR = logarithm of the minimum angle of resolution; SBP = systolic blood pressure.

history of eye injury in their left eye, diabetes-related eye disease, macular degeneration, or other serious eye conditions (except for glaucoma and cataract) in either eye. Left eyes without data on ocular comorbidities or refractive error, with high refractive errors (spherical equivalent  $>+5$  diopters [D] or  $<-6$  D), high astigmatism (absolute value of cylindrical power  $>3$  D), or a history of refractive surgery were excluded. Participants with a history of surgery or laser for glaucoma or ocular hypertension were also excluded. Of the 93 345 left eyes remained in analysis, 1208 eyes with self-reported glaucoma were excluded for analyses of CH distribution.

## Statistical Analysis

All analyses were performed using left eye data, which were captured after right eye data as specified in the study protocol. This may mean left eye data are less prone to artefact, such as blinking, in our cohort.<sup>20</sup> We included refractive error in analyses as the spherical equivalent in diopters (sphere power + 1/2 cylinder power). For glaucoma status, controls were defined as participants without self-reported glaucoma in either eye.

A descriptive analysis of CH in left eyes stratified by age, sex, and ethnicity was conducted after excluding all participants with self-reported glaucoma. One-way analysis of variance was performed to compare means of CH by age, sex, and ethnicity.

Associations between CH and other demographic, ocular, and systemic factors and self-reported glaucoma were evaluated with univariable linear regression and all factors with  $P < 0.05$  in univariable analysis were also analyzed with multivariable linear regression.

We analyzed the relationship between self-reported glaucoma and CH using the following steps:


1. Locally weighted scatterplot smoothing (LOWESS),<sup>21</sup> a method usually used to visualize the structure of data,<sup>22</sup> was used to explore the relationship between self-reported glaucoma and corneal hysteresis. The turning points found on the LOWESS curve were used as nodes for piecewise analysis.
2. Piecewise logistic regression for self-reported glaucoma and CH was performed in 3 models after adjusting for covariables.
3. The joint distribution of the proportion of self-reported glaucoma, CH, and IOPg was displayed using a 3-dimensional bar chart.

We then applied linear regression to evaluate the relationships between CH and 16 systemic diseases after adjusting for covariables.

The 3-dimensional bar chart was plotted using Excel for Office 365 (Microsoft Corp, Redmond, WA). All other analyses were performed and plots generated using STATA/SE-15 (StataCorp LLC, College Station, TX).

## Results


All analyses were performed using left eye data in this study. A total of 111 942 UK Biobank participants had available CH values for left eyes. After data cleaning as shown in Figure 1, the mean CH was  $10.60 \pm 1.88$  mmHg (95% confidence interval [CI], 10.59–10.62 mmHg) in the 92 137 eyes without self-reported glaucoma. The distribution of mean CH stratified by age, sex, and ethnicity is



**Figure 2.** Locally weighted scatterplot smoothing (LOWESS) of self-reported glaucoma and corneal hysteresis (CH), (A) unstratified, (B) stratified by age, and (C) stratified according to the tertiles of Goldmann-correlated intraocular pressure (IOPg).

summarized in Table 1. A significant difference in CH was found between participants with different ethnicities ( $P < 0.001$ ). The CH values were lower in black participants ( $9.62 \pm 1.87$  mmHg, 95% CI, 9.56–9.69 mmHg) compared with white participants ( $10.66 \pm 1.87$  mmHg, 95% CI, 10.65–10.67 mmHg). The CH was

significantly greater in female participants ( $10.79 \pm 1.86$  mmHg, 95% CI, 10.77–10.80 mmHg) compared with male participants ( $10.39 \pm 1.88$  mmHg, 95% CI, 10.37–10.40 mmHg,  $P < 0.001$ ). Overall, CH was also significantly higher in younger people across the whole age spectrum enrolled (mean  $10.91 \pm 1.91$  mmHg, 95%



**Figure 3.** Three-dimensional bar charts showing the percentage of self-reported glaucoma stratified according to tertiles of corneal hysteresis (CH) and Goldmann-correlated intraocular pressure (IOPg).



Table 3. Logistic Regression for Self-Reported Glaucoma

	Model I (n = 92 637)*		Model II (n = 92 637)†		Model III (n = 91 013)‡	
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
CH/mmHg						
≤10.1	0.78 (0.73–0.82)	6.44×10 <sup>-19</sup>	0.82 (0.78–0.87)	2.20×10 <sup>-12</sup>	0.86 (0.79–0.94)	4.96×10 <sup>-4</sup>
>10.1	0.99 (0.93–1.05)	0.70	0.94 (0.88–1.00)	0.06	1.01 (0.94–1.09)	0.76
IOPg/mmHg	–	–	1.14 (1.11–1.16)	3.05×10 <sup>-40</sup>	1.13 (1.11–1.16)	1.61×10 <sup>-21</sup>

CI = confidence interval; IOPg = Goldmann–correlated intraocular pressure; OR = odds ratio.

\*Adjusting for age, sex, and ethnicity.

†Adjusting for age, sex, ethnicity, and IOPg.

‡Adjusting for age, sex, ethnicity, IOPg, currently intraocular pressure–lowering medication (s) using (Ref. = not), diastolic blood pressure, height, visual acuity, refractive error, smoking status, alcohol drinking frequency, diabetes status, and Townsend deprivation index.

CI, 10.87–10.95 mmHg for those aged 40 to 44 years compared with 10.30±1.84 mmHg, 95% CI, 10.27–10.32 mmHg for those aged 65 to 69 years,  $P < 0.001$ ).

The associations of CH were analyzed with linear regression models as shown in Table 2. Corneal hysteresis was significantly associated with all included factors except for visual acuity and alcohol intake frequency. In the multivariable linear regression model after adjusting for covariates, CH was significantly higher in women (0.19 mmHg,  $P = 2.07 \times 10^{-27}$ ), smokers (reference: never smoked; 0.10 mmHg former smokers,  $P = 7.71 \times 10^{-13}$ ; 0.42 mmHg current smokers,  $P = 1.22 \times 10^{-84}$ ), participants with a higher Townsend deprivation index (0.01 mmHg/unit,  $P = 7.82 \times 10^{-8}$ ), and those with self-reported diabetes (0.28 mmHg,  $P = 1.25 \times 10^{-20}$ ). Corneal hysteresis was significantly lower in older participants (–0.33 mmHg/10 years,  $P < 10^{-300}$ ), black participants (reference: white; –1.22 mmHg,  $P = 1.03 \times 10^{-260}$ ), Asian participants (reference: white; –0.46 mmHg,  $P = 2.08 \times 10^{-45}$ ), participants with higher blood pressure (–0.08 mmHg/10 mmHg diastolic blood pressure,  $P = 1.29 \times 10^{-33}$ ), greater height (–0.16 mmHg/10 cm,  $P = 4.71 \times 10^{-61}$ ), greater myopia (0.03 mmHg/D,  $P = 3.06 \times 10^{-26}$ ), and those with self-reported glaucoma (–0.52 mmHg,  $P = 1.13 \times 10^{-15}$ ).

Figures 2 and 3 and Table 3 show the relationship between self-reported glaucoma and CH. Overall, lower CH was associated with a higher proportion of self-reported glaucoma. As shown in Figure 2A, when CH was less than approximately 10 mmHg, the proportion of self-reported glaucoma increased markedly when CH decreased. However, with increases in CH above 10 mmHg, the proportion of self-reported glaucoma remained relatively stable at approximately 1%. The LOWESS curve shapes were similar in analyses stratified by age (Fig 2B) and IOPg (Fig 2C), with sharp increases in the proportions of self-reported glaucoma at CH values less than approximately 10 mmHg.

Piecewise logistic regressions were performed with a node set at 10.1 mmHg (Table 3). As shown in the Supplementary Material (available at [www.aojournal.org](http://www.aojournal.org)), 10.1 mmHg was the smallest node that self-reported glaucoma and CH were significantly associated when CH was less than the node, whereas there was no association between self-reported glaucoma and CH when CH was greater than the node in all 3 models. When CH was less than 10.1 mmHg, higher CH was a protective factor for self-reported glaucoma. A 1 mmHg increase in CH was associated with an odds ratio (OR) of 0.78 (95% CI, 0.73–0.82,  $P < 0.001$ ) after adjusting for age, sex, and ethnicity in Model I, an OR of 0.82 (95% CI, 0.78–0.87,  $P < 0.001$ ) in Model II (Model I with further adjusting for IOPg), and an OR of 0.86 (95% CI, 0.79–0.94,  $P < 0.001$ ) in Model III (the maximally adjusted model). When CH exceeded 10.1 mmHg, it was not associated with self-reported glaucoma in all 3 models (Table 3).

The relationship among self-reported glaucoma, CH, and IOPg is displayed using a 3-dimensional bar chart (Fig 3). In keeping with the analyses reported in Figure 2C and Table 3, the proportion of self-reported glaucoma was highest in participants with high IOPg and low CH and lowest in the participants whose IOPg was not high and CH was not low.

We analyzed associations between CH and 16 self-reported disorders of the thyroid gland, pituitary gland, and other immunologic/systemic disorders (Table 4). Only systemic lupus erythematosus (SLE) was significantly associated with CH after correction for multiple testing ( $P < 0.003125$ , Bonferroni-corrected threshold). Corneal hysteresis was significantly higher in participants with self-reported SLE (0.55, 95% CI, 0.24–0.86 mmHg in the fully adjusted model).

## Discussion

In this large UK cohort, we have described mean CH stratified by age, sex, and ethnicity (Table 1). We found that CH was significantly lower in black participants and in older age groups, which is consistent with previously published findings.<sup>15,23</sup> Past studies indicate that CH and CCT are positively associated,<sup>24–26</sup> and CCT is negatively associated with darker skin pigmentation.<sup>27</sup> One explanation for the variation in CH by ethnicity may be differences mediated by changes in CCT. Conversely, previous publications revealed no significant association between CCT and age,<sup>7,28,29</sup> suggesting an independent association between lower CH and older age.

Corneal hysteresis was significantly higher in smokers in our cohort (both current and former smokers). A previous, smaller study had suggested this, but results were inconclusive.<sup>30</sup> The mechanisms underlying the relationship between smoking and corneal changes are unknown,<sup>31,32</sup> and the association between smoking and corneal ectatic disorders is controversial.<sup>33,34</sup> An epidemiologic study showed a marked reduction in the incidence of keratoconus among smokers,<sup>34</sup> implying altered corneal biomechanics. This is supported by experimental evidence of collagen crosslinking by formaldehyde, a constituent of cigarette smoke, with resulting increased resistance to collagenases.<sup>34</sup> Smoking has also been reported to damage the tear film<sup>35,36</sup> and possibly the corneal endothelium,<sup>37</sup> which may influence CCT and CH measurements. We

Table 4. Linear Regressions for Corneal Hysteresis and Self-Reported Disorders of the Thyroid Gland, Pituitary Gland, or Other Immunologic/Systemic Disorders\*

Corneal Hysteresis	Model 1 <sup>†</sup>		Model 2 <sup>†</sup>		Model 3 <sup>†</sup>		Prevalence <sup>‡</sup>
	Coefficient ( $\beta$ )	P	Coefficient ( $\beta$ )	P	Coefficient ( $\beta$ )	P	
Thyroid disorders							
Hyperthyroidism/thyrotoxicosis/Grave's disease	-0.02 (-0.16 to 0.12)	0.74	-0.02 (-0.16 to 0.12)	0.75	-0.04 (-0.18 to 0.10)	0.61	1.05% (0.94%)
Hypothyroidism/myxedema	0.02 (-0.04 to 0.07)	0.57	0.02 (-0.03 to 0.08)	0.43	0.02 (-0.03 to 0.08)	0.42	6.46% (6.50%)
Thyroid goiter	-0.22 (-0.43 to -0.01)	0.04 <sup>§</sup>	-0.22 (-0.43 to -0.02)	0.04 <sup>§</sup>	-0.19 (-0.39 to 0.02)	0.07	0.13% (0.40%)
Thyroiditis	0.20 (-0.26 to 0.66)	0.40	0.20 (-0.26 to 0.66)	0.39	0.21 (-0.24 to 0.67)	0.36	0.07% (0.09%)
Disorders of pituitary gland							
Acromegaly	1.09 (0.12–2.06)	0.03 <sup>§</sup>	1.11 (0.15–2.07)	0.02 <sup>§</sup>	1.22 (0.21–2.22)	0.02 <sup>§</sup>	0.02% (0.02%)
Hypopituitarism	-0.25 (-0.82 to 0.32)	0.40	-0.26 (-0.83 to 0.31)	0.38	-0.24 (-0.80 to 0.33)	0.42	0.05% (0.06%)
Hyperprolactinemia	-0.06 (-0.87 to 0.75)	0.89	-0.03 (-0.87 to 0.81)	0.95	-0.03 (-0.84 to 0.78)	0.95	0.02% (0.02%)
Pituitary adenoma/tumor	-0.09 (-0.51 to 0.34)	0.69	-0.07 (-0.49 to 0.35)	0.74	-0.02 (-0.44 to 0.39)	0.92	0.09% (0.10%)
Immunological/systemic disorders							
SLE	0.64 (0.31–0.96)	0.0001 <sup>  </sup>	0.64 (0.32–0.97)	0.0001 <sup>  </sup>	0.55 (0.24 to 0.86)	0.0006 <sup>  </sup>	0.17% (0.16%)
Sjögren's syndrome/sicca syndrome	0.10 (-0.29 to 0.48)	0.63	0.11 (-0.28 to 0.50)	0.58	0.13 (-0.26 to 0.52)	0.51	0.13% (0.11%)
Rheumatoid arthritis	0.11 (-0.01 to 0.24)	0.07	0.12 (0.00–0.24)	0.06	0.08 (-0.04 to 0.20)	0.20	1.51% (1.25%)
Vasculitis	0.04 (-0.19 to 0.27)	0.72	0.05 (-0.18 to 0.27)	0.68	0.07 (-0.16 to 0.30)	0.56	0.37% (0.39%)
Dermatopolymyositis	-0.24 (-1.02 to 0.54)	0.54	-0.25 (-1.02 to 0.52)	0.52	-0.26 (-1.05 to 0.52)	0.51	0.03% (0.02%)
Scleroderma/systemic sclerosis	0.04 (-0.62 to 0.71)	0.90	0.03 (-0.63 to 0.70)	0.92	0.07 (-0.55 to 0.70)	0.82	0.04% (0.03%)
Psoriasis	0.10 (-0.03 to 0.22)	0.12	0.10 (-0.03 to 0.22)	0.13	0.07 (-0.06 to 0.19)	0.28	1.49% (1.32%)
Sarcoidosis	-0.29 (-0.56 to -0.01)	0.04 <sup>§</sup>	-0.27 (-0.55 to 0.01)	0.06	-0.18 (-0.46 to 0.11)	0.22	0.27% (0.26%)

SLE = systemic lupus erythematosus.

\*Participants with self-reported glaucoma in either eye were excluded.

<sup>†</sup>Model I, adjusted for age, sex and ethnicity; Model II, adjusted for age, sex, ethnicity and Goldmann-correlated intraocular pressure (IOPg); Model III, adjusted for age, sex, ethnicity, IOPg, height, diastolic blood pressure, visual acuity, smoking status, refractive error, diabetes status, and Townsend deprivation index.

<sup>‡</sup>Prevalence % = Proportion using all UK Biobank participants with available data (n = 375 064). (%) = Proportion within the sample with available data after data cleaning (n = 69 973).

<sup>§</sup>P < 0.05.

<sup>||</sup>P < 0.003125 (Bonferroni-corrected threshold for multiple testing).

found no significant association between alcohol consumption and CH.

Our findings in Figures 2 and 3, and Table 3 suggest that CH may be useful in glaucoma risk stratification in clinical practice. Figure 2 and Table 3 indicate that a CH value of 10.1 mmHg could play a role as cutoff point in clinical practice to evaluate a patient's risk of glaucoma. When CH is less than 10.1 mmHg, lower CH may be associated with a higher risk of glaucoma (OR, 1.16; 95% CI, 1.07–1.26 per mmHg CH decrease in the fully adjusted model). When CH was greater than 10.1 mmHg, the rate of self-reported glaucoma remained relatively stable with further increases in CH. Medeiros et al<sup>38</sup> reported that lower CH with values below 10 mmHg was a risk factor for glaucoma progression.

Measurement of CH demonstrates good repeatability,<sup>39</sup> and there are no significant diurnal fluctuations,<sup>26,40</sup> making CH measurement a potentially attractive addition to current glaucoma risk stratification methods. Corneal hysteresis has been shown to be lower in different types of glaucoma, including open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, pseudoexfoliative glaucoma, and congenital glaucoma.<sup>41–46</sup> Lower CH is also positively associated with visual field progression.<sup>8,38</sup> Some studies have found a positive association between CH and glaucoma-related changes in optic disc morphology,<sup>47–49</sup> whereas others found no such relationship.<sup>50–52</sup> Unlike CH, IOP and CCT measurements are limited by significant diurnal variation.<sup>26,40,53–55</sup> Figures 2C and 3 and Table 3 show that CH and IOPg could be analyzed together in clinical settings to evaluate glaucoma risk, because the risk of self-reported glaucoma was highest in participants with low CH and high IOPg and lowest in participants whose IOPg was not high and CH was not low.

In analyses for associations between CH and self-reported disorders shown in Table 4, only SLE was significantly associated with CH at  $P < 0.003$  (Bonferroni-corrected threshold for multiple testing). We found that CH was significantly higher in participants with SLE, which is contradictory to the result in a case-control study that reported CH was lower in patients with SLE.<sup>56</sup> Lower CH has also been reported in thyroid eye disease;<sup>10</sup> however, we did not find an association between CH and thyroid disorders. We also did not find associations between CH and rheumatoid arthritis or psoriasis as previously published.<sup>11,12</sup> Participants with acromegaly in our cohort had higher CH values (at  $P < 0.05$ ), in agreement with findings by Ozkok et al;<sup>13</sup> however, our results were not significant after correction for multiple testing. Former studies have yielded variable results when evaluating CH in diabetes.<sup>57–60</sup> Our study shows higher CH among patients with diabetes as previously reported,<sup>60,61</sup> which is supported by the former findings that having diabetes decreased the odds of having more severe keratoconus.<sup>62</sup> The increased cross-linking of corneal collagen<sup>63</sup> in diabetes may contribute to the higher CH. However, 2 small sample studies<sup>64,65</sup> reported no significant change of CH after cross-linking operation in keratoconus. Another possible mechanism is the

morphologic<sup>66</sup> and functional alteration<sup>67</sup> of corneal endothelium in diabetic patients, leading to abnormal hydration and increased thickness of cornea,<sup>66,67</sup> which is associated with higher CH.

## Study Strengths and Limitations

The large sample size and standardized techniques are major strengths of our study, allowing us to detect and quantify small effects. However, the study is limited by the fact that all disease statuses were self-reported by participants, which can result in misclassification error.<sup>68</sup> The UK Biobank has a low response rate of 5.5%, which limits external validity. With respect to glaucoma, there will be an under-ascertainment of disease because approximately 50% of cases may not have been diagnosed.<sup>68</sup> Meanwhile, participants with ocular hypertension, suspected glaucoma, or cataracts may report a diagnosis of glaucoma. The potential impact of these errors is unknown. We excluded participants with a history of surgery or laser for glaucoma or ocular hypertension. A potential confounding variable in the reported association between CH and glaucoma is the use of IOP-lowering medications, which may significantly alter corneal biomechanical properties.<sup>9,69,70</sup> The binary variable of current, regular IOP-lowering medication use versus no use in this study may oversimplify the effects of different medications on corneal biomechanics. Corneal hysteresis and IOPg in this study were measured together using the same instrument and adjusting one for the other makes interpretation difficult. Despite this, we found a weak correlation between them (*Pearson correlation coefficient, rho* = 0.045) in the sample after data cleaning. Investigation into the association between CH and diseases including glaucoma, SLE, and diabetes is scarce, and we anticipate that future research will build on our findings.

In conclusion, our study offers CH reference values for future research and clinical practice. We also report associations between CH and age, sex, ethnicity, smoking status, refractive error, self-reported glaucoma, diabetes, and SLE, which may be important when interpreting CH. Corneal hysteresis measurement may play a role in clinical practice for glaucoma and other ocular and systemic conditions.

## References

1. Ehlers N, Bramsen T, Sperling S. Applanation tonometry and central corneal thickness. *Acta Ophthalmol.* 1975;53:34–43.
2. Whitacre MM, Stein R. Sources of error with use of Goldmann-type tonometers. *Surv Ophthalmol.* 1993;38:1–30.
3. Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on applanation tonometry. *Am J Ophthalmol.* 1993;115:592–596.
4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120:714–720.
5. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). *Ophthalmology.* 2001;108:1779–1788.



6. Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. *J Cataract Refract Surg.* 2005;31:156–162.
7. Hoffmann EM, Lamparter J, Mirshahi A, et al. Distribution of central corneal thickness and its association with ocular parameters in a large central European cohort: the Gutenberg health study. *PLoS One.* 2013;8:e66158.
8. Congdon NG, Broman AT, Bandeenroche K, et al. Central corneal thickness and corneal hysteresis associated with glaucoma damage. *Am J Ophthalmol.* 2006;141:868–875.
9. Agarwal DR, Ehrlich JR, Shimmyo M, Radcliffe NM. The relationship between corneal hysteresis and the magnitude of intraocular pressure reduction with topical prostaglandin therapy. *Br J Ophthalmol.* 2012;96:254–257.
10. Karabulut GO, Kaynak P, Altan C, et al. Corneal biomechanical properties in thyroid eye disease. *Kaohsiung J Med Sci.* 2014;30:299–304.
11. Can ME, Erten S, Can GD, et al. Corneal biomechanical properties in rheumatoid arthritis. *Eye Contact Lens.* 2015;41:382–385.
12. Celik U, Aykut V, Celik B, et al. A comparison of corneal biomechanical properties in patients with psoriasis and healthy subjects. *Eye Contact Lens.* 2015;41:127–129.
13. Ozkok A, Hatipoglu E, Tamcelik N, et al. Corneal biomechanical properties of patients with acromegaly. *Br J Ophthalmol.* 2014;98:651–657.
14. Garcia Filho CA, Prata TS, Sousa AK, et al. Intraocular pressure, corneal thickness, and corneal hysteresis in Steinert's myotonic dystrophy. *Arq Bras Oftalmol.* 2011;74:161–162.
15. Haseltine SJ, Pae J, Ehrlich JR, et al. Variation in corneal hysteresis and central corneal thickness among black, Hispanic and white subjects. *Acta Ophthalmol.* 2012;90:e626–e631.
16. Wang JK, Huang TL, Pei-Yuan S, Chang PY. Factors affecting corneal hysteresis in Taiwanese adults. *Eye Sci.* 2015;30:89–93.
17. Rice LJ, Jiang C, Wilson SM, et al. Use of segregation indices, Townsend Index, and air toxics data to assess lifetime cancer risk disparities in metropolitan Charleston, South Carolina, USA. *Int J Environ Res Public Health.* 2014;11:5510–5526.
18. Chua SYL, Thomas D, Allen N, et al. Cohort profile: design and methods in the eye and vision consortium of UK Biobank. *BMJ Open.* 2019;9:e025077.
19. Standard B. *Test Charts for Determining Distance Visual Acuity: BS 4274-1968.* London: British Standards Institution; 1968.
20. Chan MP, Grossi CM, Khawaja AP, et al. Associations with intraocular pressure in a large cohort: results from the UK Biobank. *Ophthalmology.* 2016;123:771–782.
21. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. *J Am Stat Assoc.* 1979;74:829–836.
22. Abu-Hanna A, de Keizer N. Integrating classification trees with local logistic regression in intensive care prognosis. *Artif Intell Med.* 2003;29:5–23.
23. Celebi ARC, Kilavuzoglu AE, Altiparmak UE, Cosar Yurteri CB. Age-related change in corneal biomechanical parameters in a healthy Caucasian population. *Ophthalmic Epidemiol.* 2018;25:55–62.
24. Shah S, Laiquzzaman M, Cunliffe I, Mantry S. The use of the Reichert ocular response analyser to establish the relationship between ocular hysteresis, corneal resistance factor and central corneal thickness in normal eyes. *Contact Lens Anterior.* 2006;29:257–262.
25. Mangouritsas G, Morphis G, Mourtzoukos S, Feretis E. Association between corneal hysteresis and central corneal thickness in glaucomatous and non-glaucomatous eyes. *Acta Ophthalmol.* 2009;87:901–905.
26. Kida T, Liu JHK, Weinreb RN. Effects of aging on corneal biomechanical properties and their impact on 24-hour measurement of intraocular pressure. *Am J Ophthalmol.* 2008;146:567–572.
27. Dimasi DP, Hewitt AW, Kagame K, et al. Ethnic and mouse strain differences in central corneal thickness and association with pigmentation phenotype. *PLoS One.* 2011;6:e22103.
28. Zheng Y, Huang G, Huang W, He M. Distribution of central and peripheral corneal thickness in Chinese children and adults: the Guangzhou Twin Eye Study. *Cornea.* 2008;27:776–781.
29. Wolfs RC, Klaver CC, Vingerling JR, et al. Distribution of central corneal thickness and its association with intraocular pressure: The Rotterdam Study. *Am J Ophthalmol.* 1997;123:767–772.
30. Kilavuzoglu AE, Celebi AR, Altiparmak UE, Cosar CB. The effect of smoking on corneal biomechanics. *Curr Eye Res.* 2017;42:16–20.
31. Madhukumar E, Vijayammal PL. Influence of cigarette smoke on cross-linking of dermal collagen. *Indian J Exp Biol.* 1997;35:483–486.
32. Wollensak G, Spoerl E. Collagen crosslinking of human and porcine sclera. *J Cataract Refract Surg.* 2004;30:689–695.
33. Jonas JB, Nangia V, Matin A, et al. Prevalence and associations of keratoconus in rural Maharashtra in central India: the central India eye and medical study. *Am J Ophthalmol.* 2009;148:760–765.
34. Raiskup-Wolf F, Spoerl E, Kuhlisch E, Pillunat LE. Cigarette smoking is negatively associated with keratoconus. *J Refract Surg.* 2008;24:S737–S740.
35. Altinors DD, Akça S, Akova YA, et al. Smoking associated with damage to the lipid layer of the ocular surface. *Am J Ophthalmol.* 2006;141:1016–1021.
36. Yoon K-C, Song B-Y, Seo M-S. Effects of smoking on tear film and ocular surface. *Korean J Ophthalmol.* 2005;19:18–22.
37. Sayin N, Kara N, Pekel G, Altinkaynak H. Effects of chronic smoking on central corneal thickness, endothelial cell, and dry eye parameters. *Cutan Ocul Toxicol.* 2014;33:201–205.
38. Medeiros FA, Freitas D, Lisboa R, et al. Corneal hysteresis as a risk factor for glaucoma progression: a prospective longitudinal study. *Ophthalmology.* 2013;120:1533–1540.
39. David VP, Stead RE, Vernon SA. Repeatability of ocular response analyzer metrics: a gender-based study. *Optom Vis Sci.* 2013;90:691–699.
40. Kotecha A, Crabb DP, Spratt A, Garway-Heath DF. The relationship between diurnal variations in intraocular pressure measurements and central corneal thickness and corneal hysteresis. *Invest Ophthalmol Vis Sci.* 2009;50:4229–4236.
41. Abitbol O, Bouden J, Doan S, et al. Corneal hysteresis measured with the Ocular Response Analyzer in normal and glaucomatous eyes. *Acta Ophthalmol.* 2010;88:116–119.
42. Castro DP, Prata TS, Lima VC, et al. Corneal viscoelasticity differences between diabetic and nondiabetic glaucomatous patients. *J Glaucoma.* 2010;19:341–343.
43. Kaushik S, Pandav SS, Banger A, et al. Relationship between corneal biomechanical properties, central corneal thickness, and intraocular pressure across the spectrum of glaucoma. *Am J Ophthalmol.* 2012;153:840–849.
44. Narayanaswamy A, Su DH, Baskaran M, et al. Comparison of ocular response analyzer parameters in Chinese subjects with primary angle-closure and primary open-angle glaucoma. *Arch Ophthalmol.* 2011;129:429–434.
45. Ozkok A, Tamcelik N, Ozdamar A, et al. Corneal viscoelastic differences between pseudoexfoliative glaucoma and primary open-angle glaucoma. *J Glaucoma.* 2013;22:740–745.

46. Gatziofias Z, Labiris G, Stachs O, et al. Biomechanical profile of the cornea in primary congenital glaucoma. *Acta Ophthalmol.* 2013;91:e29–e34.
47. Bochmann F, Ang GS, Azuara-Blanco A. Lower corneal hysteresis in glaucoma patients with acquired pit of the optic nerve (APON). *Graefes Arch Clin Exp Ophthalmol.* 2008;246:735.
48. Khawaja AP, Chan MP, Broadway DC, et al. Corneal biomechanical properties and glaucoma-related quantitative traits in the EPIC-Norfolk Eye Study. *Invest Ophthalmol Vis Sci.* 2014;55:117–124.
49. Prata TS, Lima VC, Guedes LM, et al. Association between corneal biomechanical properties and optic nerve head morphology in newly diagnosed glaucoma patients. *Clin Exp Ophthalmol.* 2012;40:682–688.
50. Carbonaro F, Hysi PG, Fahy SJ, et al. Optic disc planimetry, corneal hysteresis, central corneal thickness, and intraocular pressure as risk factors for glaucoma. *Am J Ophthalmol.* 2014;157:441–446.
51. Mansouri K, Leite MT, Weinreb RN, et al. Association between corneal biomechanical properties and glaucoma severity. *Am J Ophthalmol.* 2012;153:419.
52. Vu DM, Silva FQ, Haseltine SJ, et al. Relationship between corneal hysteresis and optic nerve parameters measured with spectral domain optical coherence tomography. *Graefes Arch Clin Exp Ophthalmol.* 2013;251:1777–1783.
53. Harper CL, Boulton ME, Bennett D, et al. Diurnal variations in human corneal thickness. *Br J Ophthalmol.* 1996;80:1068–1072.
54. du Toit R, Vega JA, Fonn D, Simpson T. Diurnal variation of corneal sensitivity and thickness. *Cornea.* 2003;22:205–209.
55. Sharifipour F, Farrahi F, Moghaddasi A, et al. Diurnal variations in intraocular pressure, central corneal thickness, and macular and retinal nerve fiber layer thickness in diabetics and normal individuals. *J Ophthalmic Vis Res.* 2016;11:42–47.
56. Yazici AT, Kara N, Yüksel K, et al. The biomechanical properties of the cornea in patients with systemic lupus erythematosus. *Eye.* 2011;25:1005–1009.
57. Goldich Y, Barkana Y, Gerber Y, et al. Effect of diabetes mellitus on biomechanical parameters of the cornea. *J Cataract Refract Surg.* 2009;35:715–719.
58. Kotecha A, Oddone F, Sinapis C, et al. Corneal biomechanical characteristics in patients with diabetes mellitus. *J Cataract Refract Surg.* 2010;36:1822–1828.
59. Sahin A, Bayer A, Ozge G, Mumcuoglu T. Corneal biomechanical changes in diabetes mellitus and their influence on intraocular pressure measurements. *Invest Ophthalmol Vis Sci.* 2009;50:4597–4604.
60. Scheler A, Spoerl E, Boehm AG. Effect of diabetes mellitus on corneal biomechanics and measurement of intraocular pressure. *Acta Ophthalmol.* 2012;90:e447–e451.
61. Hussnain SA, Alsberge JB, Ehrlich JR, et al. Change in corneal hysteresis over time in normal, glaucomatous and diabetic eyes. *Acta Ophthalmol.* 2015;93:e627–e630.
62. Kuo IC, Broman A, Pirouzmanesh A, Melia M. Is there an association between diabetes and keratoconus? *Ophthalmology.* 2006;113:184–190.
63. Sady C, Khosrof S, Nagaraj R. Advanced Maillard reaction and crosslinking of corneal collagen in diabetes. *Biochem Biophys Res Commun.* 1995;214:793–797.
64. Spoerl E, Terai N, Scholz F, et al. Detection of biomechanical changes after corneal cross-linking using Ocular Response Analyzer software. *J Refract Surg.* 2011;27:452–457.
65. Goldich Y, Barkana Y, Morad Y, et al. Can we measure corneal biomechanical changes after collagen cross-linking in eyes with keratoconus? A pilot study. *Cornea.* 2009;28:498–502.
66. Lee JS, Oum BS, Choi HY, et al. Differences in corneal thickness and corneal endothelium related to duration in diabetes. *Eye.* 2006;20:315–318.
67. McNamara NA, Brand RJ, Polse KA, Bourne WM. Corneal function during normal and high serum glucose levels in diabetes. *Invest Ophthalmol Vis Sci.* 1998;39:3–17.
68. Shweikh Y, Ko F, Chan MP, et al. Measures of socioeconomic status and self-reported glaucoma in the U.K. Biobank cohort. *Eye.* 2015;29:1360–1367.
69. Sun L, Shen M, Wang J, et al. Recovery of corneal hysteresis after reduction of intraocular pressure in chronic primary angle-closure glaucoma. *Am J Ophthalmol.* 2009;147:1061–1066.
70. Tsikripi P, Papaconstantinou D, Koutsandrea C, et al. The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes. *Drug Des Devel Ther.* 2013;7:1149–1156.

## Footnotes and Financial Disclosures

Originally received: March 28, 2019.

Final revision: June 7, 2019.

Accepted: June 28, 2019.

Available online: July 5, 2019.

Manuscript no. 2019-605.

<sup>1</sup> Department of Psychiatry, University of Oxford, Oxford, United Kingdom.

<sup>2</sup> National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.

<sup>3</sup> UCL Institute of Ophthalmology, London, United Kingdom.

\*Appendix 1. UK Biobank Eye and Vision Consortium Membership. UK Biobank Eye & Vision Consortium: The UK Biobank Eye & Vision Consortium members are Tariq Aslam, PhD, Manchester University, Sarah A. Barman, PhD, Kingston University, Jenny H. Barrett, PhD, University of Leeds, Paul Bishop, PhD, Manchester University, Peter Blows, BSc, NIHR Biomedical Research Centre, Catey Bunce, DSc, King's College London, Roxana O. Carare, PhD, University of Southampton, Usha Chakravarthy, FRCOphth, Queens University Belfast, Michelle Chan, FRCOphth, NIHR Biomedical Research Centre, Sharon Y.L. Chua, PhD, NIHR Biomedical Research Centre, David P. Crabb, PhD, UCL, Philippa M. Cumberland,

MSc, UCL Great Ormond Street Institute of Child Health, Alexander Day, PhD, NIHR Biomedical Research Centre, Parul Desai, PhD, NIHR Biomedical Research Centre, Bal Dhillon, FRCOphth, University of Edinburgh, Andrew D. Dick, FRCOphth, University of Bristol, Cathy Egan, FRCOphth, NIHR Biomedical Research Centre, Sarah Ennis, PhD, University of Southampton, Paul Foster, PhD, NIHR Biomedical Research Centre, Marcus Fruttiger, PhD, NIHR Biomedical Research Centre, John E. J. Gallacher, PhD, University of Oxford, David F. GARWAY-HEATH FRCOphth- NIHR Biomedical Research Centre, Jane Gibson, PhD, University of Southampton, Dan Gore, FRCOphth, NIHR Biomedical Research Centre, Jeremy A. Guggenheim, PhD, Cardiff University, Chris J. Hammond, FRCOphth, King's College London, Alison Hardcastle, PhD, NIHR Biomedical Research Centre, Simon P. Harding, MD, University of Liverpool, Ruth E. Hogg, PhD, Queens University Belfast, Pirro Hysi, PhD, King's College London, Pearse A. Keane, MD, NIHR Biomedical Research Centre, Sir Peng T. Khaw, PhD, NIHR Biomedical Research Centre, Anthony P. Khawaja, DPhil, NIHR Biomedical Research Centre, Gerassimos dos Laszaratos, PhD, NIHR Biomedical Research Centre, Andrew J. Lotery, MD, University of Southampton, Tom Macgillivray, PhD, University of Edinburgh, Sarah Mackie, PhD, University of Leeds, Keith

Martin, FRCOphth, University of Cambridge, Michelle McGaughey, Queen's University Belfast, Bernadette McGuinness, PhD, Queen's University Belfast, Gareth J. McKay, PhD, Queen's University Belfast, Martin McKibbin, FRCOphth, Leeds Teaching Hospitals NHS Trust, Danny Mityr, PhD, NIHR Biomedical Research Centre, Tony Moore, FRCOphth, NIHR Biomedical Research Centre, James E. Morgan, DPhil, Cardiff University, Zaynah A. Muthy, BSc, NIHR Biomedical Research Centre, Eoin O'Sullivan, MD, King's College Hospital NHS Foundation Trust, Chris G. Owen, PhD, University of London, Praveen Patel, FRCOphth, NIHR Biomedical Research Centre, Euan Paterson, BSc, Queens University Belfast, Tunde Peto, PhD, Queen's University Belfast, Axel Petzold, PhD, UCL, Jugnoo S. Rahi, PhD, UCL Great Ormond Street Institute of Child Health, Alicja R. Rudnikca, PhD, University of London, Jay Self, PhD, University of Southampton, Sobha Sivaprasad, FRCOphth, NIHR Biomedical Research Centre, David Steel, FRCOphth, Newcastle University, Irene Stratton, MSc, Gloucestershire Hospitals NHS Foundation Trust, Nicholas Strouthidis, PhD, NIHR Biomedical Research Centre, Cathie Sudlow, DPhil, University of Edinburgh, Dhanes Thomas, FRCOphth, NIHR Biomedical Research Centre, Emanuele Trucco, PhD, University of Dundee, Adnan Tufail, FRCOphth, NIHR Biomedical Research Centre, Veronique Vitart, PhD, University of Edinburgh, Stephen A. Vernon, DM, Nottingham University Hospitals NHS Trust, Ananth C. Viswanathan, FRCOphth, NIHR Biomedical Research Centre, Cathy Williams, PhD, University of Bristol, Katie Williams, PhD, King's College London, Jayne V. Woodside, MRCOphth, PhD, Queen's University Belfast, Max M. Yates, PhD, University of East Anglia, Jennifer Yip, PhD, University of Cambridge, and Yalin Zheng, PhD, University of Liverpool.

**Financial Disclosure(s):**

The author(s) have made the following disclosure(s): P.J.F.: Personal fees – Allergan, Carl Zeiss, Google/DeepMind, Santen; Grant – Alcon, outside the submitted work; Support – Richard Desmond Charitable Trust, via Fight for Sight, London.

A.P.K.: Supported – Moorfields Eye Charity Career Development Fellowship.

P.J.F. and A.P.K.: Salary support – National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital.

These authors acknowledge a proportion of our financial support from the UK Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology.

This analysis was funded by the Medical Research Council, UK (MRC), through a grant to Dementia Platforms UK (DPUK) - MRC grant ref MR/L023784/2 (to B.Z.). Data from UK Biobank were accessed under application number 15008 (to B.Z.) on the DPUK Data Portal. The UK Biobank Eye and Vision Consortium is supported by grants from The National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute, Moorfields Eye Charity, and the International Glaucoma Association. No funders had a direct role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication.

**HUMAN SUBJECTS:** Human subjects were included in this study. The North West Multi-centre Research Ethics Committee approved the study (Reference No., 06/MRE08/65), in accordance with the tenets of the Declaration of Helsinki. Detailed information about the study is available at the UK Biobank web site ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)). All participants provided informed consent.

No animal subjects were used in this study.

**Author Contributions:**

Conception and design: Zhang, Khawaja, Gallacher, Foster

Data collection: Zhang, Shweikh, Khawaja, Gallacher, Foster, UK Biobank Eye & Vision Consortium

Analysis and interpretation: Zhang, Shweikh, Khawaja, Gallacher, Bauermeister, Foster

Obtained funding: N/A

Overall responsibility: Zhang, Shweikh, Khawaja, Gallacher, Bauermeister, Foster

**Abbreviations and Acronyms:**

**CCT** = central corneal thickness; **CH** = corneal hysteresis; **CI** = confidence interval; **D** = diopters; **IOP** = intraocular pressure; **IOPg** = Goldmann-correlated intraocular pressure; **LOWESS** = locally weighted scatterplot smoothing; **OR** = odds ratio; **SLE** = systemic lupus erythematosus.

**Correspondence:**

Paul J. Foster, PhD, FRCS(Ed), UCL Institute of Ophthalmology, 11-43 Bath Street, London, EC1V 9EL. E-mail: [p.foster@ucl.ac.uk](mailto:p.foster@ucl.ac.uk).